SMARCC2 and Parkinson disease: Overall, the cellular SMARCC2-1A3 staining based on observations from all neurologically normal and PD cases could be categorised as (1) Nuclear punctate SMARCC2-1A3, (2) nuclear punctate SMARCC2-1A3 with a SMARCC2+ cytobody, (3) weak to no nuclear SMARCC2-1A3 with a SMARCC2+ cytobody or (4) no SMARCC2-1A3 labelling (Fig 1A–1F).